Selected Grants
BEconneCTD-ILD (BElimumab for conneCtive Tissue Disease ILD)] Phase 3, randomized, double-blind, placebocontrolled, parallel group study to evaluate the efficacy and safety of belimumab administered subcutaneously in adults with interstitial lung di
Clinical TrialPrincipal Investigator · Awarded by GlaxoSmithKline · 2024 - 2029AP01-007 Avalyn Pro00115469 A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial Evaluating the Safety and Efficacy of Pirfenidone Solution for Inhalation (AP01) in Subjects with Progressive Pulmonary Fibrosis (PPF)
Clinical TrialPrincipal Investigator · Awarded by Avalyn Pharma Inc. · 2024 - 2029FIBRONEER ON BI-1305-0031
Clinical TrialPrincipal Investigator · Awarded by Boehringer Ingelheim Pharmaceuticals, Inc. · 2024 - 2029TETON-PPF - A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Progressive Pulmonary Fibrosis (TETON-PPF)
Clinical TrialPrincipal Investigator · Awarded by United Therapeutics Corporation · 2024 - 2028BEACON PLN-74809-IPF-206. A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the treatment of idiopathic pulmonary fibrosis (BEACON)
Clinical TrialPrincipal Investigator · Awarded by Pliant Therapeutics, Inc. · 2024 - 2028A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks inpatients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
Clinical TrialPrincipal Investigator · Awarded by Boehringer Ingelheim Pharmaceuticals, Inc. · 2023 - 2027A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Idiopathic Pulmonary Fibrosis (IPF)
Clinical TrialPrincipal Investigator · Awarded by Boehringer Ingelheim Pharmaceuticals, Inc. · 2023 - 2027Daewoong A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of DWN12088 in Patients With Idiopathic Pulmonary Fibrosis
Clinical TrialPrincipal Investigator · Awarded by Daewoong Pharmaceutical Co., Ltd · 2023 - 2027Idiopathic Pulmonary Fibrosis Prespective Outcomes (IPF-PRO) Registry
Clinical TrialPrincipal Investigator · Awarded by Boehringer Ingelheim Pharmaceuticals, Inc. · 2014 - 2025AZ ORIN1001-002 D4325C00001: Phase 1b Double-Blind, Placebo-Controlled, Ascending Dose Trial: ORIN1001 in Subjects with Idiopathic Pulmonary Fibrosis
Clinical TrialPrincipal Investigator · Awarded by ORINOVE, Inc · 2022 - 2024Evaluate Efficacy and Safety of CC-90001 in Subjects with Idiopathic Pulmonary Fibrosis
Clinical TrialPrincipal Investigator · Awarded by Celgene Corporation · 2017 - 2024FGCL-3019-095 Pro00108483 Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects with Idiopathic Pulmonary Fibrosis (IPF)
Clinical TrialPrincipal Investigator · Awarded by Fibrogen, Inc. · 2022 - 2024WA42293 PRM-151-303: A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PRM-151 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS
Clinical TrialPrincipal Investigator · Awarded by Genentech, Inc. · 2022 - 2024ND-L02-s0201-005 Phase 2 randomized double blind placebo controlled study to evaluate safety, tolerability, biological activity, and PK of ND-L02-s0201 in subjects with IPF
Clinical TrialPrincipal Investigator · Awarded by Nitto Denko Corporation · 2018 - 2023WA42294 PRM-151: A PHASE III OPEN-LABEL EXTENSION STUDY TO EVALUATE LONG-TERM SAFETY AND EFFICACY OF PRM-151 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF)
Clinical TrialPrincipal Investigator · Awarded by Genentech, Inc. · 2022 - 2023Novartis VAY736: A subject, investigator, and sponsor blinded randomized placebo controlled multicenter study to investigate VAY736 in patients with idiopathic pulmonary fibrosis
Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2018 - 2023Pulmonary Fibrosis Foundation Biomarker and/or Patient Registry Protocols
ResearchPrincipal Investigator · Awarded by Regents of the University of Michigan · 2015 - 2023GLPG1690-CL-304 A Phase 3 randomized double blind parallel group, placebo controlled multicenter study to evaluate efficacy and safety of 2 doses of GLPG1690 in addition to local standard of care
Clinical TrialPrincipal Investigator · Awarded by Galapagos NV · 2019 - 2023BI 1199.248 INBUILD-ON An open label extension trial of the long term safety of nintedanib in patients with progressive fibrosing interstitial lung disease.
Clinical TrialPrincipal Investigator · Awarded by Boehringer Ingelheim Corporation · 2019 - 2023Respivant RVT1601-CC-04 SCENIC: Randomized double blind placebo controlled dose ranging efficacy and safety study with inhaled RVT-1601 for the treatment of persistent cough in patients with IPF
Clinical TrialPrincipal Investigator · Awarded by Respivant Sciences, GmbH · 2019 - 2020A 52-week, double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of Nintedanib, 150 mg twice daily, in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
Clinical TrialPrincipal Investigator · Awarded by Boehringer Ingelheim Corporation · 2017 - 2020Care Center Network Charter Agreement
ConferencePrincipal Investigator · Awarded by Pulmonary Fibrosis Foundation · 2016 - 2019A 24-week, double-blind, randomized, parallel-group study evaluating the efficacy and safety of oral nintedanib co-administered with oral sildenafil, compared to treatment with nintedanib alone, in patients with idiopathic pulmonary fibrosis (IPF)
Clinical TrialPrincipal Investigator · Awarded by Boehringer Ingelheim Corporation · 2016 - 2018Promedior PRM-151
Clinical TrialPrincipal Investigator · Awarded by Promedior, Inc · 2016 - 2017CHEST ADVANCED CLINICAL TRAINING PROGRAM-Idiopathic Pulmonary Fibrosis
ConferenceCo-Director · Awarded by Chest Foundation · 2016 - 2016Idiopathic Pulmonary Fibrosis Clinical Research Network
Clinical TrialCo Investigator · Awarded by National Institutes of Health · 2005 - 2014External Relationships
- Boehringer Ingleheim
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.